Background: D2 procedure has been accepted as the standard lymphadenectomy for advanced GC, while the role of No.14v lymph node (14v) dissection for distal GC is still controversial. Methods: A total of 284 GC patients receiving D2 plus 14v dissection in our center were enrolled. Patients were categorized into two groups based on 14v status: positive group (PG) and negative group (NG). Clinicopathological factors correlated with 14v metastasis and prognostic variables were respectively analyzed. Results: Thirty-five patients (12.3%) had 14v metastasis. Metastasis to No.4d and No.6 lymph node were independent variables affecting 14v metastasis. Patients with positive 14v had a significant lower 3-year overall survival (OS) rate than those without (3-year OS: 42.9% vs. 70.3%, P < 0.001). Multivariable analysis demonstrated that 14v status was an independent prognostic factor for III stage GC (hazard ratio 1.462, 95% confident interval: 1.182-2.309, P = 0.027). The prognosis of 14v positive patients correlated with tumor size and No.6 lymph node status in univariate analysis. Conclusion: GC patients with No.4d and No.6 lymph node metastasis were more likely to have positive 14v. Status of 14v was an independent prognostic factor for III stage GC. Patients with 14v metastasis usually had a poorer prognosis, while survival in such patients after curative surgery was similar to that of patients staged IIIc without 14v metastasis.
Introduction
Radical gastrectomy with D2 lymph node dissection has become increasingly regarded as the standard surgical procedure for most patients with operable GC (1) (2) (3) (4) (5) . Lymph nodes along the superior mesenteric vein are referred to as No.14v lymph node. In the second English edition of Japanese Classification of Gastric Carcinoma, 14v is included in the N2 group and should be removed in D2 lymphadenectomy for tumors located in the lower third of the stomach (6) . However, the third English edition of Japanese gastric cancer treatment guidelines excludes 14v from D2 lymphadenectomy, though it is still defined as regional gastric lymph node (5, 7) . Previous studies have affirmed the poor survival of 14v positive GC patients (8) (9) ). An et al. found the metastatic rate of 14v was merely 6.6% and 14-v metastasis was a poor prognostic factor, and should be regarded as distant metastasis (8) . Masuda et al. reported most patients with 14v metastasis had a poor prognosis, similar to those with systemic metastasis (9) . However, 14-v positive GC patients with long-term survival after curative resection are not uncommon in clinical practice (10) (11) (12) (13) .
Until now, the data of 14v was mainly from Japan and Korea, where the early GC was very common. It was reported that the incidence of 14v metastasis was merely 1.3% in early-stage GC, and it raised 19 .7% in advanced stage (8) . The correlated factors of 14v metastasis and its prognostic value have been analyzed in Japan and Korea, but have not been investigated worldwide (8, 9, 11, 14, 15) . The necessity of 14v dissection is still controversial in GC surgery. The aim of the present study is to elucidate the risk factors for 14v metastasis and its potential impact on the long-term outcome for GC patients after surgery in a single high-volume center in China.
Materials and methods

Patients
A total of 1598 patients with GC who underwent surgical resection in the department of gastric cancer; Tianjin Medical University Cancer Institute and Hospital between January 2003 and March 2011 were eligible for this study. Eligibility criteria for this study included: (1) adenocarcinoma of the stomach, (2) no history of gastrectomy or other malignancy, (3) no history of neoadjuvant chemotherapy, (4) receiving D2 plus 14v dissection, (5) no distant metastasis, (6) patients were completely followed-up and (7) no patients died during the initial hospital stay or for 1 month after surgery. After excluding four patients with gastric neuroendocrine carcinoma, one patient with gastric squamous cells carcinoma, 1062 patients without 14v dissection, 20 remnant GC patients, 14 patients with other malignant tumors, 38 patients accepted neoadjuvant chemotherapy, 72 patients received less than standard D2 lymph node dissection, 23 patients died within 1 months after surgery, 53 patients lost and 27 patients with distant metastasis, Ultimately, 284 patients were enrolled in this study.
Evaluation of clinicopathological variables, survival and therapeutic value index
No.14v lymph nodes are defined as the lymph nodes along the superior mesenteric vein. There are no predefined indications of dissection of the 14v lymph node. The removal of 14v lymph nodes absolutely depended on the surgeons' willingness and habits. To completely dissect the 14v lymph nodes, the soft tissue around the superior mesenteric vein must be removed along with exposing the superior mesenteric vein.
Potential risk factors for 14v metastasis analyzed included sex, age at surgery, tumor location, tumor diameter, Borrmann type, histology, depth of invasion, lymph node metastasis, extranodal metastasis and other 1-12a regional lymph nodes. The following possible prognostic factors were also evaluated: sex, age at surgery, tumor location, tumor diameter, Borrmann type, histology, extranodal metastasis, curability, TNM stage, postoperative chemotherapy, type of gastrectomy and status of 14v.
The therapeutic value index (TVI) of lymph node dissection proposed by Sasako et al. was calculated by multiplying the frequency of metastasis to the station by the 5-year OS rate of patients with metastasis to that station (15) . In the present study, as we only got 3-year OS rate, the TVI was evaluated by multiplying metastatic rate of the station by the 3-year OS rate of patients with metastasis to that station.
The tumors were staged according to the seventh edition Union for International Cancer Control TNM classification system, whereas lymphadenectomy and lymph node stations were defined according to the third English Edition of the Japanese Classification of Gastric Carcinoma (7). Tumors were classified into two groups based on histology: differentiated type, including papillary, well or moderately differentiated adenocarcinoma; and undifferentiated type, including poorly differentiated or undifferentiated adenocarcinoma, signet ring cell carcinoma and mucinous carcinoma.
Follow up
The patients were followed up every 3 months up to 2 years after surgery, then every 6 months up to 5 years, and then every year or until death. Physical examination, laboratory test, Chest X-ray and abdominal ultrasound (US) were performed at each visit, while endoscopy and abdominal computed tomography (CT) were obtained every 6 months or each year. The overall survival rate was calculated from the day of surgery until time of death or final follow-up. The median follow-up was 41 months (range: 2-110). The date of final follow-up was 30 April 2014.
Statistical analysis
For continuous variables, which were presented as mean [95% CI (confidence interval)], parametric analysis was performed using Student's t test. Categorical variables were analyzed by means of the chi-square or Fisher's exact test. A logistic regression analysis was used to identify the independent risk factors correlated with 14v metastasis. Overall survival curves were calculated using the Kaplan-Meier method based on the length of time between primary surgical treatment and final follow-up or death. The log-rank test was used to assess statistical differences between curves. Independent prognostic factors were identified by Cox proportional hazards regression model. P < 0.050 (bilateral) was considered statistically significant. The statistical analysis was performed using the statistical analysis program package SPSS 18.0 (SPSS, Chicago, IL, USA).
Results
Patients and lymph nodes
Two hundred and eighty-four patients included 183 males (64.4%) and 101 females (35.6%). The age ranges from 19 to 86 years, and the median age was 56 years. Of the 284 GC patients who underwent gastrectomy, 270 patients had a R0 resection, and 14 patients ended up with an R1 resection. One hundred and seventy-four patients received postoperative adjuvant chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin (folfox6) or capecitabine and oxaliplatin (Xelox).
As shown in Table 1 , patients with 14v metastasis had a larger number of other regional nodal stations (No.1-12a) involved and a larger number of positive nodes in the other regional stations, as well as a larger number of lymph nodes retrieved from station of 14v. The number of nodes dissected did not vary as a function of 14v invasion, either at the total level or at the other regional level.
Potential risk factors for 14v metastasis
Of the 284 patients who underwent a 14v dissection, 35 (12.3%) patients had 14v metastasis. The frequency of 14v metastasis according to tumor location and depth of invasion is shown in Table 2 . Of the 60 GC patients with upper tumors, only two patients had 14v metastasis. And for tumors without serosal invasion, only one cases demonstrated 14v metastasis. However, the frequency of 14v metastasis rose to 14.0% and 18.8% for tumors invading serosa and adjacent structure, respectively. In tumors which invaded to serosa and adjacent structure and located at middle and lower of the stomach, the frequency of 14v metastasis was as high as 17.1%.
All the patients were categorized into two groups based on 14v status: positive group (PG) and negative group (NG). As a result, 35 patients were assigned to PG, and 249 patients to NG. Clinicopathological factors were compared in Table 3 . There were no statistical difference in sex, age, tumor diameter, histology, extranodal metastasis, curability, type of gastrectomy and postoperative chemotherapy between the two groups, while factors including tumor location (middle and lower), Borrmann type (III/IV), depth of invasion (T4), N stage (N2-3) and regional lymph nodes such as 1, 3, 4 sb, 4d, 5, 6, 7, 8a, 9, 11p and 12a metastasis were correlated with 14v metastasis in univariate analysis. In multivariate analysis, only No.4d [relative risk (RR): 2.615, 95% CI: 1.068-6.402, P = 0.035] and No.6 (RR: 3.336, 95% CI: 1.387-8.024, P = 0.007) lymph node metastasis were independently associated with 14v metastasis. Table 4 details the therapeutic value of lymph node dissection based on the calculated TVI. The TVI of station 14v lymph node was 5.3, similar to that of station 5 (5.6) or 12a (5.6) lymph nodes, but greater than that of station 2, 10, 11p or 11d lymph nodes.
Therapeutic value of lymph node dissection
Prognostic value of 14v status
A total of 10 factors evaluated in univariate analysis had a significant effect on survival: age at surgery, tumor location, tumor diameter, Borrmann type, histology, extranodal metastasis, curability, TNM stage, type of gastrectomy and status of 14v. GC patients with 14v metastasis had a significant lower 3-year OS rate than those without (3-year OS: 42.9% versus 70.3%, P < 0.001). Survival of 14v positive patients was similar to that of patients staged IIIc without 14v metastasis (3-year OS rate: 42.9% versus 38.9%, P = 0.643) (Fig. 1A) . In multivariate analysis, only age at surgery, tumor diameter and TNM stage were independently associated with OS, and the status of 14v was not an independent prognostic factor for the whole study series (Table 5) .
As patients with 14v metastasis were mainly at III stage, we particularly focused on III stage GC patients. The 3-year OS rates were 42.9% and 57.3% for III GC patients with and without 14v metastasis, respectively (P = 0.005). Multivariate analysis revealed that status of 14v, tumor diameter and TNM stage (IIIc) were independent prognostic factors for III GC patients ( Table 5) .
Survival of 14v positive GC patients without other distant metastasis
To evaluate the prognosis of 14v positive patients, 27 patients with other distant metastasis were used for comparison. It was affirmed that 14v positive GC patients without other distant metastasis had a significant better survival than those M1 diseases (3-year OS: 42.% versus 7.4%, P < 0.001) (Fig. 1B) . Potential prognostic factors evaluated for GC patients with 14v metastasis included sex, age at surgery, tumor location, tumor diameter, Borrmann type, histology, extranodal metastasis, curability, postoperative chemotherapy, type of gastrectomy, TNM stage, No.6 and No.4d lymph node status. Only tumor diameter and No.6 lymph node status were found to be significant prognostic factors in univariate analysis ( Fig. 2A,B) . Patients received adjuvant postoperative chemotherapy demonstrated a better survival than those without, though the difference was not significant (Fig. 2C ).
Discussion
The extent of lymphadenectomy has been a hot issue in GC surgery. Though D2 dissection has been confirmed to be associated with increased survival and acceptable mortality and morbidity compared with limited D1 dissection (1-2), can more extended lymphadenectomy of D2 plus 14v dissection bring any benefits? The answer is uncertain. The prognosis and stage of GC with 14v metastasis is still controversial as well (7) (8) (9) . This study demonstrates that No.4d and No.6 lymph node metastasis were independently associated with 14v metastasis, and GC patients with 14v metastasis had a poorer prognosis than those without, survival of such patients without other distant metastasis correlated with tumor diameter and No.6 lymph node status, and status of 14v was an independent prognostic factor for III stage GC patients. According to the second English edition of Japanese classification of gastric carcinoma, No.14v lymph nodes are referred as lymph nodes along the superior mesenteric vein and defined as regional GC lymph nodes, and the lymph nodes are included in D2 lymphadenectomy for distal advanced GC (6) . However, the third edition of the 'guideline' excludes it from D2 gastrectomy as several retrospective studies affirmed the poor survival of 14v-positive patients even after a curative resection, meanwhile, the guideline also emphasizes that D2 plus 14v dissection may be beneficial for patients who are suspected to harbor metastasis to the No.6 nodes (7-9). As for 14v, the current fourth edition 'guideline' is consistent with the previous version (5). The role of 14v lymphadenectomy for advanced GC is still debatable. So it is vital important to identify risk factors associated with 14v metastasis. The rate of 14v metastases in T1a and T1b GC is reported to be lower: 0.0% and 0.7%, respectively (16). Masuda et al. reported the incidence of 14v metastasis was merely 1.3% in early GC, and it raised 19.7% in advanced stage (9) . In the study by An et al., the metastatic rate of 14v was 11.0% in N2 stage and 40.5% in N3 stage, and in N1 stage, only 1.2% patients had positive 14v (8) . According to our data, of the 60 GC patients with upper tumors, only two patients had 14v metastasis. And for tumors without serosal invasion, only one cases demonstrated 14v metastasis. However, in tumors which invaded to serosa and adjacent structure and located at middle and lower of the stomach, the frequency of 14v metastasis was as high as 17.1%. Meanwhile, patients with 14v metastasis tended to have a larger number of positive lymph nodes and more locoregional nodal stations (1-11, 12a) The necessity of lymph node dissection was based on metastatic pathway, frequency and its impact on survival. Sasako et al. proposed a simple index which was calculated by multiplying the frequency of metastasis to the station by the 5-year survival rate of patients with metastasis to that station to evaluate to actual benefit of each node dissection (15) . This therapeutic index was accepted worldwide and several studies had affirmed the therapeutic index for 14v lymph node dissection in distal GC was equivalent to that for most second-tier lymph nodes, thus removal of 14v was suggested (11, 14, 15) . Our results were consistent to the previous studies, and we found the therapeutic index of 14v was similar to that of No.5 and No.9 lymph nodes which were included in D2 dissection for advanced GC. From this point of view, it was reasonable to add 14v dissection to D2 category.
Until now, the prognostic impact of 14v metastasis is still uncertain. An et al. demonstrated that the survival of 14v-positive patients was even worse than that of patients with Stage IV GC without 14v metastasis, they concluded that GC patients with 14v metastasis should be regarded as M1 disease (8). Masuda et al. found the prognosis of most patients with 14v metastasis was similar to those with systemic metastasis, while some such patients without No.16 lymph node metastasis may benefit from a curative resection (9). Abe et al. shared a case of Stage I GC with two nodal metastases to No.6 demonstrated early recurrence at nodal station No.14v four months after D1+ dissection, however, the patients still survived without recurrence 5.5 years after resection of recurrence nodes. They considered some patients with a No.6 metastasis may benefit from a No.14v lymphadenectomy, even in early-staged disease (10) . In the present study, the 3-year OS of GC patients with 14v metastasis was significantly decreased compared with those without, however, patients with 14v metastasis but without other distant metastasis demonstrated a better survival than those IV stage diseases and 14v status was confirmed to be an independent prognostic factor for III GC. Another interesting finding of this study is that the 3-year OS rates are significantly decreasing as metastasis to No. (17) . However, several studies has affirmed some patients may benefit form a D2 plus para-aortic nodal dissection (18) (19) (20) . Recently, a prospective study from Japan even revealed that 4-weekly S-1 plus cisplatin followed by D2 lymphadenectomy with No.16 lymph node dissection was effective for locally advanced GC with bulky lymph node metastasis along the coeliac artery and its branches and/or para-aortic nodal metastasis (20 (21, 22) . Our previous study also demonstrated that adding 14v to a D2 lymphadenectomy led to improved OS and lower lymph node recurrence rate for distal GC patients with TNM IIIb/IIIc disease (23) . In the present study, it was affirmed that survival in patients with 14v metastasis was similar to that of patients staged IIIc without 14v involved. To identify appropriate treatment for 14v positive patients, survival of 14v positive GC patients without other distant metastasis was also analyzed. It was reported that there was no OS difference between M0 and M1 disease, and no independent prognostic factor in patients with 14v-positive GC (8) . Our result was different from the previous study. We found prognosis of 14v positive patients was significantly correlated with tumor diameter and No.6 lymph node status, and 14v positive GC patients with No.6 metastasis had a significant higher 3-year OS rate that those without. This may indicate other metastatic pathway to 14v station is present in 14v positive patients without No.6 metastasis. Patients with 14v lymph nodes involved via No.6 metastasis are curable by surgical resection. However, even the early GC, presence of positive 14v may suggest that the disease was at a late stage and with high risk of recurrence (10) . So these patients should be closely followed-up and more seriously treated with adjuvant chemotherapy.
Conclusions
Until now, as no random prospective trail has been implemented to affirm survival benefit in 14v dissection, and the number of patients with 14v metastasis was small in the present study, we could not draw any definite conclusion. However, considering the results of those retrospective studies, we concluded that patients with 14v metastasis had a poorer prognosis, while such patients without other distant metastasis may benefit from a curative resection, and after curative surgery, the survival of these patients was similar to that of patients staged IIIc without 14v metastasis, besides, status of 14v was an independent prognostic factor for III GC.
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